Dr Reddy’s Pens Patent Licensing Agreement with Takeda to Commercialise Vonoprazan

Dr Reddy’s Laboratories on Thursday, July 18, announced that it has entered into a non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan tablets in India.

Key Takeaways from Licensing Agreement

• Dr Reddy’s Laboratories has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited.
• The agreement allows Dr Reddy’s to commercialise Vonoprazan tablets in India.
• Dr Reddy’s will market Vonoprazan tablets under its own trademark VONO.
• The tablets will be available in two strengths: 10mg and 20mg.

Vonoprazan is an orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders. 

The company will market Vonoprazan tablets under its own trademark VONO that will be available in two strengths - 10mg and 20mg.

“The non-exclusive patent licensing agreement with Takeda is part of our continuous efforts to make innovative medicines available to patients in India through strategic collaborations to meet unmet needs and enhance standard of care", MV Ramana, CEO – Branded Markets at Dr Reddy’s said. 

“Leveraging our expertise in this therapy area, we are pleased to make the first-in-class drug Vonoprazan (Vono™) available to patients in India”, Ramana added.

About Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited is a multinational pharmaceutical firm headquartered in India that was founded in 1984. The firm provides a wide range of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter (OTC). Its primary clinical areas of interest are gastrointestinal, cardiovascular, diabetology, cancer, pain management, and dermatology. 

Reddy's business segments include Pharmaceutical Services and Active Ingredients, Global Generics, and others. The Pharmaceutical Services and Active Ingredients section focuses on the Company's manufacture and marketing of APIs and intermediates. The Global Generics segment includes the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for patient consumption, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations. 

About Vonoprazan

Vonoprazan is a novel type of pharmaceutical that suppresses stomach acid production more efficiently than previous medications. It is a Potassium Competitive Acid Blocker (PCAB) that inhibits a particular mechanism in stomach cells. Unlike typical acid-reducing drugs, Vonoprazan begins to act immediately after the initial dosage, lasts longer in the body, helps regulate nightly acid production, and may be used at any time. It is licensed to treat a wide range of disorders, including acid reflux, stomach and intestinal ulcers, ulcers induced by some pain drugs, and H. pylori infections.

You can check Dr. Reddy's Laboratories Limited share price to make informed investment decision.